3Roman G C, Salloway S, Black S E, etal. Randomized, placebo controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size[J]. Stroke, 2010,41(6) : 1213-1221.
4Kavirajan H, Schneider L S. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia; a meta analysis of randomised controlled trials[J]. Lancet Neurol, 2007,6(9) ; 782-792.
5Dichgans M, Markus H S, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL[J]. Lancet Neurol, 2008,7(4) :310-318.
6Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial[J]. Lancet, 2002,359(9314):1283- 1290.
7Ballard C, Sauter M, Scheltens P, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia; the Vantage study[J]. Curr Med Res Opin, 2008,24(9);2561-2574.
8Wilcock G, Mobius H J, Stoffler A. A double blind, placebocontrolled multicentre study of memantine in mild to moderate vascular dementia ( MMM500 ) [ J ]. Int Clin Psychopharmacol, 2002,17 (6) : 297-305.
9Meyer J S, Judd B W, Tawaklna T, et al. Improved cognition after control of risk factors for multi- infarct dementia [ J ]. JAMA,1986,256(16) :2203-2209.
10Forette F, Seux M L, Staessen J A, et al. The prevention of dementia with antihypertensive treatment; new evidence from the Systolic Hypertension in Europe (Syst-Eur) study[J]. Arch Intern Med,2002,162(18);2046- 2052.
8Petersen R C, Stevens J C, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology [J]. Neurology, 2001,56(9):1133-1142.
9Petersen R C, Smith G E, Waring S C, et al. Mild cognitive impairment: clinical characterization and outcome[J]. Arch Neurol,1999,56(3) :303-308.
10Mayeux R. Epidemiology of neurodegeneration[J]. Annu Rev Neurosci, 2003,26 (1) 81-104.
7Capsoni S, Ugolini G, Comparini A, et al. Alzheimer-like neurodcgeneration in aged antinerve growth factor transgenic mice[J]. Proc Natl Acad Sci USA,2000,97(12):6826-6831.
8Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse[J]. Nature, 1999,400(6740) : 173-177.
9Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease[J]. Nature, 2000,408(6815) : 982-985.
10Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease[J]. Nature, 2000,408 (6815) : 979- 982.
